Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2006 December; 7(4): E99.
Published online 2014 March 30. doi:  10.1208/pt070496
PMCID: PMC2750333

Aqueous, oil, and ointment formulations of ketorolac: efficacy against prostaglandin E2-induced ocular inflammation and safety: A technical note

Summary and Conclusions

The efficacy of aqueous, oil, and ointment formulations of ketorolac against PGE2-induced ocular inflammation in rabbits was evaluated, with monitoring of blinking rate and PMN and protein migration in tear fluid, following topical PGE2 instillation. Ketorolac ophthalmic formulations protected the eye against inflammatory insult. Chronic topical administration of formulations for 10 days into rats' eyes did not lead to any appreciable gastrointestinal ulceration, which indicates that the formulations are safe for long-term use.

Full Text

The Full Text of this article is available as a PDF (194K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Hall DWR, Jaitly KD. Inflammatory responses of the rabbit eye to prostaglandins. Agents Actions. 1977;2:123–133. [PubMed]
2. Kass MA, Podos SM, Moses RA, Backer B. Prostaglandin E1 and aqueous humor dynamics. Invest Ophthalmol. 1972;11:1022–1027. [PubMed]
3. Eakins KE. Prostaglandin and non-prostaglandin mediated breakdown of the blood-aqueous barrier. Exp Eye Res. 1977;25:483–498. doi: 10.1016/S0014-4835(77)80043-2. [PubMed] [Cross Ref]
4. Srinivasan BD, Kulkarni PS. The role of arachidonic acid metabolites in the mediation of the polymorphonuclear leukocyte response following corneal injury. Invest Ophthalmol Vis Sci. 1980;19:1087–1093. [PubMed]
5. Berman MB, Barber JC, Talamo RC, Langley CE. Corneal ulceration and the serum antiproteases, I: alpha 1-antitrypsin. Invest Ophthalmol. 1973;12:759–770. [PubMed]
6. Woodward DF, Ledgard SE. Effect of LTD4 on conjunctival vasopermeability and blood aqueous barrier integrity. Invest Ophthalmol Vis Sci. 1985;26:481–485. [PubMed]
7. Anderson JA, Leopold LH. Antiproteolytic activities found in human tears. Ophthalmology. 1981;88:82–84. doi: 10.1016/S0161-6420(81)35073-8. [PubMed] [Cross Ref]
8. Rooks WH, Tomolonis AJ, Maloney PJ, Wallach MB, Schuler ME. The analgesic and anti-inflammatory profile of (±)-5-benzoyl-1, 2-dihydro-3H-pyrrolo [1,2a] pyrrole-1-carboxylic acid (RS-37619) Agents Actions. 1982;12:684–690. doi: 10.1007/BF01965079. [PubMed] [Cross Ref]
9. Flach AJ, Kraff MC, Sanders DR, Tanenbaum L. The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on post-surgical blood aqueous barrier. Arch Ophthalmol. 1988;106:480–483. doi: 10.1001/archopht.1988.01060130526028. [PubMed] [Cross Ref]
10. Heier J, Cheetham JK, Degryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. Am J Ophthalmol. 1999;127:253–259. doi: 10.1016/S0002-9394(98)00413-9. [PubMed] [Cross Ref]
11. Solomon KD, Cheetham JK, Degryse R, Brint SF, Rosenthal A. Topical ketorolac tromethamine 0.5% opthalmic solution in ocular inflammation after cataract surgery. Ophthalmology. 2001;108:331–337. doi: 10.1016/S0161-6420(00)00543-1. [PubMed] [Cross Ref]
12. Fraser-Smith EB, Mathews TR. Effect of ketorolac on Candida albicans ocular infection in rabbit. Arch Ophthalmol. 1987;105:264–267. doi: 10.1001/archopht.1987.01060020118042. [PubMed] [Cross Ref]
13. Fraser-Smith EB, Mathews TR. Effect of ketorolac on Pseudomonas aeruginosa ocular infection in rabbits. J Ocul Pharmacol. 1988;4:101–109. doi: 10.1089/jop.1988.4.101. [PubMed] [Cross Ref]
14. Price FW, Price MO, Zeh W, Dobbins K. Pain reduction after laser in situ keratomileusis with ketorolac tromethamine ophthalmic solution 0.5%: a randomized, double-masked, placebo-controlled trial. J Refract Surg. 2002;18:140–144. [PubMed]
15. Mahoney JM, Waterbury LD. (±)-5-benzoyl-1, 2-dihydro-3H-pyrrolo [1, 2a] pyrrole-1-carboxylic acid (RS-37619): a non-irritating ophthalmic anti-inflammatory agent. Invest Ophthalmol Vis Sci. 1983;24:151–159.
16. Malhotra M, Majumdar DK. Effect of preservative, antioxidant and viscolizing agents on in vitro transcorneal permeation of ketorolac tromethamine. Indian J Exp Biol. 2002;40:555–559. [PubMed]
17. Malhotra M, Majumdar DK. In vitro transcorneal permeation of ketorolac from oil based ocular drops and ophthalmic ointment. Indian J Exp Biol. 1997;35:1324–1330. [PubMed]
18. Malhotra M, Majumdar DK. In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil and ointment formulations to normal corneas of rabbits: a technical note. AAPS Pharm Sci Tech. 2005;6:E523–E526. doi: 10.1208/pt060365. [PMC free article] [PubMed] [Cross Ref]
19. Pharmacopoeia of India. 2nd ed. Delhi, India: Government of India, Ministry of Health and Family Welfare; 1970:203.
20. Abelson MB, Butrus SI, Kliman GH, Larson DL, Corey EJ, Smith LM. Topical arachidonic acid: a model for screening anti-inflammatory agents. J Ocul Pharmacol. 1987;3:63–74. doi: 10.1089/jop.1987.3.63. [PubMed] [Cross Ref]
21. Sood R. Medical Laboratory Technology: Methods and Interpretations. 4th ed. New Delhi, India: Jaypee Brothers; 1999. pp. 169–237.
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–275. [PubMed]
23. Singh S, Majumdar DK. Evaluation of anti-inflammatory activity of fatty acids of Ocimum sanctum fixed oil. Indian J Exp Biol. 1997;35:380–383. [PubMed]
24. Maurice DM, Mishima S. Ocular pharmacokinetics. In: Sears ML, editor. Handbook of Experimental Pharmacology: Pharmacology of the Eye. Berlin-Heildelberg, Germany: Springer-Verlag; 1984. pp. 19–103.
25. Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology. 5th ed. Edinburgh, Scotland: Churchill Livingstone; 2003. pp. 217–243.
26. Pillinger MH, Capodici C, Rosenthal P, et al. Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci USA. 1998;95:14540–14545. doi: 10.1073/pnas.95.24.14540. [PubMed] [Cross Ref]
27. Katzung BG. Basic & Clinical Pharmacology. 9th ed. Boston, MA: McGraw-Hill; 2004. pp. 576–603.
28. Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics. 3rd ed. Philadelphia, PA: Lea & Febiger; 1984. pp. 85–112.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists